As of November 6, 2026, GRI Bio, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 4, 2026 (Form 8-K, November 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like GRI Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
GRI Bio, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-04. Every row below is cited to the filing it comes from, and this page adds each new change as GRI Bio, Inc. files it.
Also on the record for GRI Bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 5.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 9.99% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Lincoln Alternative Strategies LLC | — | 5%+ stakes | Source |
| December 29, 2025 | Stake report, Schedule 13G, by Lincoln Alternative Strategies LLC | 11.83% of the class | 5%+ stakes | Source |
| December 17, 2025 | Stake report, Schedule 13G, by Mitchell P. Kopin | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs GRI Bio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on GRI Bio, Inc. and the records around it.
GRI Bio, Inc. elsewhere on the record
Companies that share a holder
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch GRI Bio, Inc.
Get an email when GRI Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on GRI Bio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on GRI Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on GRI Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-04 | Reported | not named in the filing | 8-K, 2026-11-04 |
New leaders reset buying decisions — get the Full Report on GRI Bio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at GRI Bio, Inc., with the record behind each one.
Find candidates like senior executive at GRI Bio, Inc.Every change, in the filing's words
Reported
Votes For Votes Against Votes Abstained Broker Non-Votes W. Marc Hertz, Ph.D. 206,059 32,542 3,438 684,435 David Szekeres 204,761 35,933 1,345 684,435 Proposal 2 Ratification of the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Of the Company's 2,186,115 shares of common stock issued and outstanding and eligible to vote as of the record date of September 22, 2026, a quorum of 926,474 shares, or approximately 42.37% of the eligible shares, was present in person or represented by proxy at the Annual Meeting.
- Each of the matters set forth below is described in detail in the Company's Proxy Statement.
- The following actions were taken at the Annual Meeting: Proposal 1 Election of the following nominees to the Company's Board of Directors, each to serve as Class III directors until the Company's 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified.
- Votes For Votes Against Votes Abstained Broker Non-Votes 883,489 23,019 19,966 - Proposal 3 Approval of an amendment and restatement to the Company's Amended and Restated 2018 Equity Incentive Plan to (i) increase the aggregate number of shares of common stock available for issuance thereunder by 546,529 and (ii) extend the evergreen provision to January 1, 2036.
- Votes For Votes Against Votes Abstained Broker Non-Votes 136,205 102,978 2,856 684,435 Proposal 4 Approval of any postponement or adjournment of the Annual Meeting, from time to time, if necessary to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to adopt the proposals set forth in the proxy statement.
Tools for this story
Each opens in a new tab, filled in for GRI Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.